Stockreport

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts [Seeking Alpha]

ArriVent BioPharma, Inc.  (AVBP) 
PDF Firmonertinib has continued to deliver encouraging efficacy with a tolerable safety profile across treated patients. Under conservative assumptions, there is an asymm [Read more]